Publications by authors named "L Hegyi"
Article Synopsis
- TP53 mutations are linked to chemoresistance in chronic lymphocytic leukaemia (CLL) and can indicate the ineffectiveness of standard chemoimmunotherapy, prompting a need for better mutation assessment.* -
- In a study of 901 CLL patients, 17.5% had TP53 mutations, with nearly half being low-burden mutations, which raises questions about their clinical significance.* -
- Low-burden TP53 mutations led to earlier treatment initiation compared to patients without mutations, suggesting the need to reconsider the detection threshold for these mutations in diagnostics.*
Introduction: Donor-derived cell-free DNA (dd-cfDNA) is a blood biomarker detecting graft injury with high negative predictive value. While non-invasive strategies for heart transplant (HTx) rejection surveillance are widely adopted in the United States with centralized testing, data on the feasibility of dd-cfDNA assay at the local level are lacking. Here, we report the first 6 months of experience with a local laboratory-run dd-cfDNA assay in the routine clinical surveillance setting.
View Article and Find Full Text PDFBackground: Recurrent genetic lesions provide basis for risk assessment in pediatric acute lymphoblastic leukemia (ALL). However, current prognostic classifiers rely on a limited number of predefined sets of alterations.
Methods: Disease-relevant copy number aberrations (CNAs) were screened genome-wide in 260 children with B-cell precursor ALL.